Newsroom | 27181 results

RICHMOND, Va.--(BUSINESS WIRE)--Accendra Health, Inc. (NYSE: ACH) (the “Company”) today announced the expiration and final results of the previously announced offers to exchange (the “Exchange Offers”) any and all of the Company’s outstanding 4.500% Senior Notes due 2029 (the “2029 Notes”) and 6.625% Senior Notes due 2030 (the “2030 Notes” and, together with the 2029 Notes, the “Existing Notes”). As of 5:00 P.M., New York City time, on June 23, 2026 (the “Expiration Time”), the Company received...

東京--(BUSINESS WIRE)--（ビジネスワイヤ） -- ASP Japan合同会社（以下、ASP Japan）は、ALLClear™ Technologyを搭載したSTERRAD™ 100NX※システム向けに、十二指腸内視鏡を含む軟性内視鏡の滅菌に対応する「Ultra GI™ サイクル」を発売しました。 Ultra GI™ サイクルは、複雑な構造を有する十二指腸内視鏡の再処理に対応する滅菌サイクルです。十二指腸内視鏡の再処理において、従来多くの施設で実施されている高水準消毒に加え、より高い水準の安全性を目指す選択肢として、過酸化水素ガスプラズマ滅菌による新たな提案を行います。 本邦においては、既に富士フイルム株式会社製の十二指腸用処置スコープ 電子内視鏡 ED-840T十二指腸用処置スコープ ED-840T に対する滅菌の適合性を取得しており、今後、医療現場における十二指腸内視鏡の再処理の質と安全性の向上を提案しています。 十二指腸内視鏡の再処理に求められる、より高い安全性 十二指腸内視鏡は、鉗子起上装置などの複雑な構造を有しており、洗浄・消毒・乾燥を含む再処理工程におい...

AU, Suiza y PRINCETON, Nueva Jersey--(BUSINESS WIRE)--Araris Biotech AG, una empresa que desarrolla una cartera diferenciada de terapias basadas en conjugados anticuerpo-fármaco (ADC), y Taiho Oncology, Inc., dedicada al desarrollo y la comercialización de tratamientos innovadores para neoplasias hematológicas y tumores sólidos, ambas pertenecientes al grupo Taiho, han anunciado hoy la dosificación del primer paciente en un ensayo clínico de fase 1 de ARC-02, un conjugado anticuerpo-fármaco dir...

AU, Svizzera e PRINCETON, N.J.--(BUSINESS WIRE)--Araris Biotech AG, azienda che promuove una pipeline diversificata di terapie a base di farmaci anticorpo-coniugati (“ADC”), e Taiho Oncology, Inc., società specializzata nello sviluppo e nella commercializzazione di nuovi trattamenti per neoplasie ematologiche maligne e tumori solidi, entrambi membri del gruppo Taiho, oggi hanno annunciato che il primo paziente ha ricevuto il trattamento in uno studio clinico di fase 1 su ARC-02, un farmaco anti...

AU, Suisse et PRINCETON, New Jersey--(BUSINESS WIRE)--Araris Biotech AG, société développant un portefeuille différencié de thérapies par conjugués anticorps-médicament (« ADC »), et Taiho Oncology, Inc., société développant et commercialisant de nouveaux traitements pour les hémopathies malignes et les tumeurs solides, toutes deux membres du groupe Taiho, ont annoncé aujourd'hui que, dans le cadre d'un essai clinique de phase 1, le premier patient avait reçu une dose d'ARC-02, un conjugué anti...

AU, Schweiz & PRINCETON, New Jersey--(BUSINESS WIRE)--Die Araris Biotech AG, ein Unternehmen, das eine differenzierte Pipeline von Therapien auf Basis von Antikörper-Wirkstoff-Konjugaten („ADCs“) vorantreibt, sowie Taiho Oncology, Inc., ein Unternehmen, das neuartige Therapien für hämatologische Malignome und solide Tumoren entwickelt und vermarktet – beide Unternehmen gehören zur Taiho-Gruppe –, gaben heute bekannt, dass der erste Patient im Rahmen einer klinischen Phase-1-Studie mit ARC-02, e...

MCLEAN, Va.--(BUSINESS WIRE)--Claritev Corporation (“Claritev” or the “Company”) (NYSE: CTEV), a technology, data and insights company focused on making healthcare more affordable, transparent and fair for all, today announced that members of its management team will participate in the Truist Securities Healthcare Disruptors & Digital Health Conference, including a panel discussion titled “The Data Before the AI: Building the Foundation for Scalable Healthcare Intelligence” with Michael Kim...

LAS VEGAS--(BUSINESS WIRE)--Black Hat, the cybersecurity industry’s most established and in-depth security event series, today announced a partnership with HIMSS, the world's leading authority in healthcare technology, to launch the inaugural Healthcare Summit at Black Hat USA 2026 (August 1–6). This historic collaboration marks the first time these two organizations have joined forces to address the critical intersection of cybersecurity and healthcare. The Healthcare Summit will take place on...

MIAMI & HOUSTON--(BUSINESS WIRE)--The Society for Neuro-Oncology (SNO), the world's largest multidisciplinary organization dedicated to advancing research, education, and clinical care for patients with brain and spinal cord tumors, and OpenEvidence, the leading AI-powered clinical decision support platform, today announced a landmark partnership, designating OpenEvidence as SNO's official generative AI partner. As part of the collaboration, SNO will embed OpenEvidence across its member-facing...

DALLAS--(BUSINESS WIRE)--Hallmark Health Care Solutions (Hallmark) today unveiled healthcare’s first Workforce Operating System, a new, AI-enabled platform that helps health systems and physician groups to manage their largest expense and greatest asset: their workforce. This missing layer in the healthcare tech stack is built on Hallmark’s years of experience helping health systems and large medical groups nationwide through a unique combination of technology, data, and workforce expertise. He...